Comparative Pharmacology
Head-to-head clinical analysis: DRISDOL versus HECTOROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRISDOL versus HECTOROL.
DRISDOL vs HECTOROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drisdol (ergocalciferol) is a vitamin D2 analog that increases intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and stimulates bone mineralization by binding to vitamin D receptors, which regulate gene expression.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
50,000 IU orally once weekly for 8 weeks, then 50,000 IU orally once monthly for maintenance.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
None Documented
None Documented
Terminal elimination half-life is approximately 19–48 hours after a single oral dose, with clinical context: repetitive dosing increases half-life due to accumulation in adipose tissue, leading to a functional half-life of weeks to months for vitamin D stores.
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Primarily excreted via bile into feces (~90%), with renal excretion accounting for the remainder (~10%). Biliary excretion of metabolites is the major route, with enterohepatic recycling contributing to prolonged elimination.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog